Abstract: The present document describes compounds that are inhibitors of coronavirus proteases, and more particularly to compounds that are inhibitors of SARS-CoV-2 viral proteases. Also, the present document describes methods and uses of the compounds for the treatment or prevention of viral infection, such as SARS-CoV-2 infections, in a subject in need of treatment.

Abstract: The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.

Abstract: The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.

Abstract: Provided are lacZ&agr; gene fragments which have been modified to introduce multiple restriction enzyme sites. Vectors according to the present invention include at least one promoter operatively linked to a DNA sequence encoding lacZ&agr;(&agr;-peptide); multiple cloning sites cleavable by distinct restriction enzymes which have been introduced within a lacZ coding sequence from and including the codon for amino acid 8, and in the lacZ coding sequence downstream of the codon for amino acid 8, in forming the modified lacZ&agr; coding sequence; and a replicon. Also provided are methods of using the vectors wherein a DNA molecule is cloned into at least one restriction enzyme site in the modified lacZ&agr; coding sequence, in forming recombinant vectors; introducing the recombinant vectors into competent host cells; growing the host cells in the presence of a chromogenic substrate cleavable by &bgr;-galactosidase; and screening for indicia of lac operon marker inactivation.

Abstract: Provided are lacZ.alpha. gene fragments which have been modified to introduce multiple restriction enzyme sites. Vectors according to the present invention include at least one promoter operatively linked to a DNA sequence encoding lacZ.alpha. (.alpha.-peptide); multiple cloning sites cleavable by distinct restriction enzymes which have been introduced within a lacZ coding sequence from and including the codon for amino acid 8, and in the lacZ coding sequence downstream of the codon for amino acid 8, in forming the modified lacZ.alpha. coding sequence; and a replicon. The vector may further comprise one or more additional features useful for protein expression and other molecular manipulations. Also provided are methods of using the vectors wherein a DNA molecule is cloned into at least one restriction enzyme site in the modified lacZ.alpha.

Abstract: The present invention relates to recombinant .beta.-1,3-glucanase essentially free of proteases. The enzyme is obtained through the use of a recombinant DNA expression vector which comprises a DNA sequence encoding the .beta.-1,3-glucanase gene or mutants and variants thereof placed under the control of an exogenous expression promoter, preferably a bacterial promoter. Also, the .beta.-1,3-glucanase gene may include sequences flanking the open reading frame of the native .beta.-1,3-glucanase gene. The present invention also relates to a microorganism transformed with a recombinant DNA expression vector comprising the .beta.-1,3-glucanase gene or mutants and variants thereof under the control of an exogenous expression promoter.

Abstract: The present invention relates to an approach for conducting site-directed mutagenesis using double-stranded DNA templates. The approach involves the development of a method for generating structures capable of directing full-length complementary-strand synthesis from double-stranded plasmid DNA. These structures are formed following heat denaturation and cooling of linearized plasmid DNA molecules in the presence of what is referred to as a "closing oligonucleotide". A "closing oligonucleotide" is a single-stranded oligonucleotide consisting of a sequence complementary to either or both free ends of one of the two plasmid DNA strands. The "closing oligonucleotide" therefore functions as an agent for recircularization of a DNA strand and generation of a primer-circular template structure suitable for polymerase-dependent full-length complementary-strand synthesis and ligation into a covalently-closed heteroduplex DNA molecule.